Remdesivir was nonfederal hospitals’ costliest drug expense two years in a row despite a 58.1 percent drop in expenditures from 2021 to 2022, according to research published April 24 in the American Journal of Health-System Pharmacy.
Read the full post on Becker's Hospital Review - Healthcare News
